Assay Development for Superior Understanding of Response and Efficacy (ASSURE)

Location:	South Carolina
Posted:	Nov 17, 2025
Due:	Dec 18, 2025
Agency:	HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Type of Government:	Federal
Category:	A - Research and development
Solicitation No:	RRPV-26-07-ASSURE
Publication URL:	To access bid details, please log in.

Active

Contract Opportunity

Notice ID

RRPV-26-07-ASSURE

Related Notice

Department/Ind. Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub-tier

OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Office

ASPR BARDA DIV CONTRACTS MGMT & ACQ

Looking for contract opportunity help?

(opens in new window)

APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.

APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.

The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).

General Information

Contract Opportunity Type: Solicitation (Original)
Original Published Date: Nov 17, 2025 01:14 pm EST
Original Date Offers Due: Dec 18, 2025 01:00 pm EST
Inactive Policy: 15 days after date offers due
Original Inactive Date: Jan 02, 2026
Initiative:
- None

Classification

Original Set Aside: No Set aside used
Product Service Code: AN42 - HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH
NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Place of Performance:
SC 29486

USA

Description

The ASSURE program aims to develop innovative, multiplexed, high-throughput, scalable and sample sparing assays that provide comprehensive evaluation of an individual’s immune status as a response to either infection or vaccination.

This program seeks to de-risk the development of novel assay platform technologies with the ultimate goal of establishing new, qualified assays primarily for BARDA and vaccine developers to comprehensively assess the immune response and status elicited by vaccines and/or infection due to CBRN threats, pandemic influenza, or other emerging infectious diseases. Some of these assays may lead to support of new correlates of protection.

Attachments/Links

Contact Information

Contracting Office Address

200 C Street, SW
Washington , DC 20515
USA

Primary Point of Contact

Rebecca Harmon
rebecca.harmon@ati.org
Phone Number 843.760.3358

Secondary Point of Contact

History

Nov 17, 2025 01:14 pm ESTSolicitation (Original)

Assay Development for Superior Understanding of Response and Efficacy (ASSURE)

See also